Monica Fedele

Prof. Monica Fedele

National Research Council - CNR
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
Alfredo FuscoAlfredo Fusco
Alfredo Fusco
Monica FedeleMonica Fedele
Monica Fedele

Verified
Journal Article
Open access
PDF file
Monica FedeleMonica Fedele
Monica Fedele
Laura CerchiaLaura Cerchia
Laura Cerchia
SPSilvia Pegoraro
Silvia Pegoraro
RSRiccardo Sgarra
Riccardo Sgarra
Guidalberto ManfiolettiGuidalberto Manfioletti
Guidalberto Manfioletti
Glioblastoma (GBM) is an extremely aggressive tumor of the central nervous system, with a prognosis of 12–15 months and just 3–5% of survival over 5 years. This is mainly because most patients suffer recurrence after treatment that currently consists in maximal resection followed by radio- and chemotherapy with temozolomide. The recurrent tumor shows a more aggressive behavior due to a phenotypic shift toward the mesenchymal subtype. Proneural-mesenchymal transition (PMT) may represent for GBM the equivalent of epithelial–mesenchymal transition associated with other aggressive cancers. In this review we frame this process in the high degree of phenotypic inter- and intra-tumor heterogeneity of GBM, which exists in different subtypes, each one characterized by further phenotypic variability in its stem-cell compartment. Under the selective pressure of different treatment agents PMT is induced. The mechanisms involved, as well as the significance of such event in the acquisition of a multitherapy resistance phenotype, are taken in consideration for future perspectives in new anti-GBM therapeutic options.

1 June 2006 in Cancer Cell
Verified
Journal Article
Closed access
Monica FedeleMonica Fedele
Monica Fedele
Rosa VisoneRosa Visone
Rosa Visone
IMIvana De Martino
Ivana De Martino
GTGiancarlo Troncone
Giancarlo Troncone
DPDario Palmieri
Dario Palmieri
Alfredo FuscoAlfredo Fusco
Alfredo Fusco

29 May 2005 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Daniela P. FotiDaniela P. Foti
Daniela P. Foti
Eusebio ChiefariEusebio Chiefari
Eusebio Chiefari
Monica FedeleMonica Fedele
Monica Fedele
RIRodolfo Iuliano
Rodolfo Iuliano
LBLeonardo Brunetti
Leonardo Brunetti
Antonio BrunettiAntonio Brunetti
Antonio Brunetti

7 May 2002 in Oncogene
Verified
Journal Article
Closed access
PDF file
Monica FedeleMonica Fedele
Monica Fedele
SBSabrina Battista
Sabrina Battista
LKLawrence Kenyon
Lawrence Kenyon
Gustavo BaldassarreGustavo Baldassarre
Gustavo Baldassarre
VFVincenzo Fidanza
Vincenzo Fidanza
Alfredo FuscoAlfredo Fusco
Alfredo Fusco

Verified
Journal Article
Open access
PDF file
Monica FedeleMonica Fedele
Monica Fedele
RSRiccardo Sgarra
Riccardo Sgarra
SBSabrina Battista
Sabrina Battista
Laura CerchiaLaura Cerchia
Laura Cerchia
Guidalberto ManfiolettiGuidalberto Manfioletti
Guidalberto Manfioletti
The transition between epithelial and mesenchymal phenotype is emerging as a key determinant of tumor cell invasion and metastasis. It is a plastic process in which epithelial cells first acquire the ability to invade the extracellular matrix and migrate into the bloodstream via transdifferentiation into mesenchymal cells, a phenomenon known as epithelial–mesenchymal transition (EMT), and then reacquire the epithelial phenotype, the reverse process called mesenchymal–epithelial transition (MET), to colonize a new organ. During all metastatic stages, metabolic changes, which give cancer cells the ability to adapt to increased energy demand and to withstand a hostile new environment, are also important determinants of successful cancer progression. In this review, we describe the complex interaction between EMT and metabolism during tumor progression. First, we outline the main connections between the two processes, with particular emphasis on the role of cancer stem cells and LncRNAs. Then, we focus on some specific cancers, such as breast, lung, and thyroid cancer.